Role of apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus from the National Lipid Association

The following is a National Lipid Association (NLA) Expert Clinical Consensus on the role of apolipoprotein (apo)B in adult patient care. This document is meant to clarify the role of apoB testing for clinicians who manage cardiovascular risk and lipid disorders, as well as health systems, payers, and medical associations. The 2021 NLA Scientific Statement, Lipid Measurements in the Management of section. Diseases,1 outlined the clinical chemistry of apoB measurement and suggested a rationale for the use of apoB within a comprehensive review of all the clinical lipid and lipoprotein measures. We invite readers to review that document and refer to this Expert Clinical Consensus as its companion. This Expert Clinical Consensus summarizes the evidence for apoB measurement in routine and specialty clinic lipid management to inform ASCVD risk assessment and decisions regarding initiation or intensification of therapies for lowering atherogenic lipoprotein burden.

Clinician Infographic View Statement Patient Infographic